These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19368985)

  • 1. Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC.
    Bral S; Duchateau M; De Ridder M; Everaert H; Tournel K; Schallier D; Verellen D; Storme G
    Radiother Oncol; 2009 Jun; 91(3):438-42. PubMed ID: 19368985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily megavoltage computed tomography in lung cancer radiotherapy: correlation between volumetric changes and local outcome.
    Bral S; De Ridder M; Duchateau M; Gevaert T; Engels B; Schallier D; Storme G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1338-42. PubMed ID: 20638192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].
    Schmücking M; Baum RP; Bonnet R; Junker K; Müller KM
    Pathologe; 2005 May; 26(3):178-89. PubMed ID: 15800765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating tumor response of non-small cell lung cancer patients with ¹⁸F-fludeoxyglucose positron emission tomography: potential for treatment individualization.
    Toma-Dasu I; Uhrdin J; Lazzeroni M; Carvalho S; van Elmpt W; Lambin P; Dasu A
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):376-84. PubMed ID: 25636761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
    Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
    J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
    van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study.
    van Baardwijk A; Bosmans G; Boersma L; Wanders S; Dekker A; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1394-401. PubMed ID: 18258380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC.
    Agrawal V; Coroller TP; Hou Y; Lee SW; Romano JL; Baldini EH; Chen AB; Jackman DM; Kozono D; Swanson SJ; Wee JO; Aerts HJ; Mak RH
    Lung Cancer; 2016 Dec; 102():1-8. PubMed ID: 27987576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
    Lee DH; Kim SK; Lee HY; Lee SY; Park SH; Kim HY; Kang KW; Han JY; Kim HT; Lee JS
    J Thorac Oncol; 2009 Jul; 4(7):816-21. PubMed ID: 19487962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?
    Abramyuk A; Tokalov S; Zöphel K; Koch A; Szluha Lazanyi K; Gillham C; Herrmann T; Abolmaali N
    Radiother Oncol; 2009 Jun; 91(3):399-404. PubMed ID: 19168248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect?
    Siker ML; Tomé WA; Mehta MP
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):135-41. PubMed ID: 16839704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer.
    Kunst PW; Lee P; Paul MA; Senan S; Smit EF
    J Thorac Oncol; 2007 Oct; 2(10):912-5. PubMed ID: 17909353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.